









市场行情
/
股票
/
nasdaq-biib
/

Biogen Inc

BIIB

187.620USD

+1.620+0.87%

收盘 01/09, 16:00（美东）报价延迟15分钟

27.52B总市值

17.07市盈率 TTM



Biogen Inc

187.620

+1.620+0.87%

概览公司财务分析

概览

公司

财务

分析

关于 Biogen Inc 公司

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Biogen Inc简介



公司代码BIIB

公司名称Biogen Inc

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

员工数量7605

证券类型Ordinary Share

年结日Sep 17

公司地址225 Binney Street

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02142

电话17814642000

网址https://www.biogen.com/

公司代码BIIB

上市日期Sep 17, 1991

CEOViehbacher (Christopher A)

Biogen Inc公司高管



名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+20082.00%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+3160.00%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+3921.00%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+167.00%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+2370.00%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-2223.00%

Mr. Jesus B. Mantas

Independent Director

8.42K

+2370.00%

Ms. Priya Singhal, M.D.

Executive Vice President, Head of Development

5.77K

-517.00%

Dr. Maria C. Freire, Ph.D.

Independent Director

5.47K

+2370.00%

Ms. Susan Langer

Independent Director

3.79K

+2370.00%

名称

名称/职务

职务

持股

持股变动

Ms. Susan H. Alexander, Esq., J.D.

Executive Vice President, Chief Legal Officer

56.35K

+20082.00%

Ms. Caroline D. Dorsa

Independent Chairman of the Board

29.22K

+3160.00%

Dr. Ginger Gregory, Ph.D.

Chief Human Resources Officer, Executive Vice President

17.50K

+3921.00%

Ms. Nicole Murphy

Executive Vice President - Pharmaceutical Operations and Technology

14.22K

+167.00%

Dr. Stephen A. Sherwin, M.D.

Independent Director

12.35K

+2370.00%

Mr. Rachid Izzar

Executive Vice President, Head of Global Product Strategy and Commercialization

11.23K

-2223.00%

收入明细

单位: USD更新时间: 1月6日周二

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

MS product revenues-TYSABRI

827.20M

32.64%

Spinal Muscular Atrophy-SPINRAZA

533.30M

21.04%

MS product revenues-Fumarate

382.80M

15.10%

MS product revenues-Interferon

246.90M

9.74%

Biosimilar product revenues-BENEPALI

121.90M

4.81%

其他

422.60M

16.67%

地区USD

名称

营收

占比

United States

1.37B

54.18%

Rest of world

911.60M

35.96%

United states-Revenues from anti-CD20 therapeutic

493.90M

19.49%

Rest of World-Other revenues

151.20M

5.97%

业务

地区

业务USD

名称

营收

占比

MS product revenues-TYSABRI

827.20M

32.64%

Spinal Muscular Atrophy-SPINRAZA

533.30M

21.04%

MS product revenues-Fumarate

382.80M

15.10%

MS product revenues-Interferon

246.90M

9.74%

Biosimilar product revenues-BENEPALI

121.90M

4.81%

其他

422.60M

16.67%

股东统计

更新时间: 1月4日周日

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

11.73%

PRIMECAP Management Company

10.19%

BlackRock Institutional Trust Company, N.A.

5.60%

State Street Investment Management (US)

4.99%

Wellington Management Company, LLP

2.89%

其他

64.59%

持股股东

占比

The Vanguard Group, Inc.

11.73%

PRIMECAP Management Company

10.19%

BlackRock Institutional Trust Company, N.A.

5.60%

State Street Investment Management (US)

4.99%

Wellington Management Company, LLP

2.89%

其他

64.59%

股东类型

持股股东

占比

Investment Advisor

52.76%

Investment Advisor/Hedge Fund

26.60%

Hedge Fund

8.04%

Pension Fund

2.94%

Research Firm

2.45%

Sovereign Wealth Fund

1.59%

Bank and Trust

1.59%

Individual Investor

0.17%

Family Office

0.15%

其他

3.72%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

2010

137.76M

93.90%

-6.74M

2025Q3

2054

139.52M

98.56%

+3.73M

2025Q2

2076

135.78M

99.30%

-133.40K

2025Q1

2125

136.05M

101.20%

-12.08M

2024Q4

2114

138.28M

98.83%

+2.02M

2024Q3

2089

135.94M

98.13%

+100.43K

2024Q2

2100

135.44M

97.85%

-355.51K

2024Q1

2106

135.99M

97.60%

-5.88M

2023Q4

2136

135.17M

94.89%

+4.09M

2023Q3

2150

131.42M

95.94%

-1.80M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

17.21M

11.73%

-2.37K

-0.01%

Sep 30, 2025

PRIMECAP Management Company

14.95M

10.19%

-847.42K

-5.36%

Sep 30, 2025

BlackRock Institutional Trust Company, N.A.

8.21M

5.6%

+19.35K

+0.24%

Sep 30, 2025

State Street Investment Management (US)

7.32M

4.99%

-149.06K

-2.00%

Sep 30, 2025

Wellington Management Company, LLP

4.25M

2.89%

-551.92K

-11.50%

Sep 30, 2025

Geode Capital Management, L.L.C.

4.07M

2.77%

+150.63K

+3.84%

Sep 30, 2025

Point72 Asset Management, L.P.

3.87M

2.64%

+41.17K

+1.07%

Sep 30, 2025

Norges Bank Investment Management (NBIM)

2.26M

1.54%

-61.02K

-2.62%

Jun 30, 2025

Invesco Capital Management LLC

2.13M

1.45%

+90.48K

+4.43%

Sep 30, 2025

BlackRock Asset Management Ireland Limited

1.89M

1.29%

+95.29K

+5.32%

Sep 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Invesco Biotechnology & Genome ETF

5.49%

First Trust NASDAQ Pharmaceuticals ETF

4.45%

iShares Neuroscience and Healthcare ETF

4.25%

First Trust NYSE Arca Biotechnology Index Fund

3.53%

VanEck Biotech ETF

3.46%

Invesco Pharmaceuticals ETF

3.01%

iShares Health Innovation Active ETF

2.81%

First Trust Health Care Alphadex Fund

2.4%

ProShares Ultra Nasdaq Biotechnology

2.22%

Alger Russell Innovation ETF

2.21%

Invesco Biotechnology & Genome ETF

占比5.49%

First Trust NASDAQ Pharmaceuticals ETF

占比4.45%

iShares Neuroscience and Healthcare ETF

占比4.25%

First Trust NYSE Arca Biotechnology Index Fund

占比3.53%

VanEck Biotech ETF

占比3.46%

Invesco Pharmaceuticals ETF

占比3.01%

iShares Health Innovation Active ETF

占比2.81%

First Trust Health Care Alphadex Fund

占比2.4%

ProShares Ultra Nasdaq Biotechnology

占比2.22%

Alger Russell Innovation ETF

占比2.21%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Biogen Inc的前五大股东是谁？



Biogen Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：17.21M，占总股份比例：11.73%。
PRIMECAP Management Company持有股份：14.95M，占总股份比例：10.19%。
BlackRock Institutional Trust Company, N.A.持有股份：8.21M，占总股份比例：5.60%。
State Street Investment Management (US)持有股份：7.32M，占总股份比例：4.99%。
Wellington Management Company, LLP持有股份：4.25M，占总股份比例：2.89%。